By: Colby Strong From: cancertherapyadvisor.com Concurrent chemoradiotherapy is tolerable and reduces pain better than radiotherapy alone for patients with breast cancer and painful bone metastases, according to research published in the Journal of Bone Oncology. The randomized, phase 2 study included 84 patients with breast cancer and painful bone metastases. The patients were randomly assigned to radiotherapy only (42 patients) …
The Thanksgiving Holiday and Breast Cancer
View PostPerlmutter Cancer Center Radiation Oncologist Works to Minimize Side Effects of Radiation
Source: nyulangone.org As a radiation oncologist, Naamit K. Gerber, MD, associate professor in the Department of Radiation Oncology at NYU Grossman School of Medicine, provides the latest and most advanced treatments to people who have breast cancer and lymphoma. Dr. Gerber is co-director of the Breast Cancer and Hematologic Malignancies Disease Management Groups at NYU Langone Health’s Perlmutter Cancer Center, …
Chemo Creates Leaky Blood Vessels Helping Cancer Cells To Spread
From: technologynetworks.com A new study adds to the evidence that chemotherapy enhances cancer’s spread beyond the primary tumor, showing how one chemo drug allows breast cancer cells to squeeze through and attach to blood vessel linings in the lungs. The research in mice leaves no doubt that the chemo drug caused changes to non-cancer cells that enable this process. Scientists …
Erica Mayer, MD, on Updated HER2- Breast Cancer Guidelines
By: Jeff Minerd From: medpagetoday.com New ASCO recommendations highlight genomic profiling and novel agents ASCO has published two sets of updated guidelines for patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer, both in the Journal of Clinical Oncology. One of the updates (Burstein et al.) covers endocrine treatment and targeted therapy for patients with hormone receptor …
Gilead, Merck to study combination therapy for breast cancer
By: PBR Staff Writer From: pharmaceutical-business-review.com Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC). Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients …
The Wonderful People in Our Lives
View Post10,000 women needed for trial that could revolutionise breast cancer treatment
By: Emily Morgan From: itv.com We may all know that survival rates from breast cancer in the UK are some of the worst in the developed world but it’s no less shocking each time we hear it. Perhaps unsurprisingly America has the best rates at 90.2%, with the UK on 85.6%. Spain, Ireland and Austria lag behind but most nations …
Providers are requesting fewer preoperative MRIs for breast cancer patients
By: Hannah Murphy From: healthimaging.com Providers are requesting fewer preoperative MRI exams for breast cancer patients, but a new analysis suggests more can be done to align with evidence-based guidelines. In 2016 the American Society of Breast Surgeons published “Choosing Wisely,” which opposed the preoperative use of MRI in breast cancer patients. The document cited multiple concerns with the practice—increased need for …
Men with Stage IV breast cancer who are receptive to systemic therapy benefit from surgery
Source: American College of Surgeons From: news-medical.net Men with Stage IV breast cancer and known estrogen (ER) and progesterone receptor (PR) status benefit from surgical intervention and from trimodal therapy (systemic therapy, surgery, and radiation), according to a study presented at the virtual American College of Surgeons (ACS) Clinical Congress 2021. The National Comprehensive Cancer Network guidelines to treat men …